Caitong International Asset Management Co. Ltd Purchases 267 Shares of Medpace Holdings, Inc. $MEDP

Caitong International Asset Management Co. Ltd increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6,675.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 271 shares of the company’s stock after acquiring an additional 267 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in Medpace were worth $85,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Invesco Ltd. grew its position in Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after acquiring an additional 102,015 shares during the last quarter. Mawer Investment Management Ltd. bought a new stake in Medpace during the 1st quarter worth $212,131,000. AQR Capital Management LLC grew its position in Medpace by 12.4% during the 1st quarter. AQR Capital Management LLC now owns 539,547 shares of the company’s stock worth $158,470,000 after acquiring an additional 59,361 shares during the last quarter. TD Asset Management Inc grew its position in Medpace by 15.6% during the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after acquiring an additional 61,764 shares during the last quarter. Finally, Northern Trust Corp grew its position in Medpace by 36.0% during the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock worth $102,830,000 after acquiring an additional 89,347 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insiders Place Their Bets

In related news, VP Susan E. Burwig sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the transaction, the vice president directly owned 57,500 shares of the company’s stock, valued at approximately $27,600,000. This represents a 14.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares in the company, valued at approximately $4,654,350. This trade represents a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 107,465 shares of company stock worth $49,720,216 in the last quarter. 20.30% of the stock is currently owned by company insiders.

Medpace Price Performance

Shares of Medpace stock opened at $605.20 on Friday. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $625.00. The stock’s 50-day moving average is $503.13 and its 200 day moving average is $391.27. The firm has a market cap of $17.00 billion, a price-to-earnings ratio of 42.32, a PEG ratio of 3.53 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter in the prior year, the company earned $3.01 EPS. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on MEDP. Rothschild & Co Redburn downgraded Medpace from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Jefferies Financial Group lifted their target price on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a report on Tuesday, September 9th. Truist Financial lifted their target price on Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Robert W. Baird set a $613.00 target price on Medpace in a report on Friday. Finally, Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, Medpace has a consensus rating of “Reduce” and a consensus target price of $464.00.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.